Your browser doesn't support javascript.
loading
Genetic Polymorphism of Mismatch Repair Genes and Susceptibility to Prostate Cancer.
Khooshemehri, Paniz; Jamaldini, Seyed Hamid; Ziaee, Seyed Amir Mohsen; Afshari, Mahdi; Sattari, Mahshid; Narouie, Behzad; Sotoudeh, Mehdi; Montazeri, Vahideh; Sarhangi, Negar; Hasanzad, Mandana.
Affiliation
  • Khooshemehri P; Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. paniz.khooshemehri@gmail.com.
  • Jamaldini SH; Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Ziaee SAM; Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Afshari M; Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran.
  • Sattari M; Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Narouie B; Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran.
  • Sotoudeh M; Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Montazeri V; Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran.
  • Sarhangi N; Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Hasanzad M; Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Urol J ; 17(3): 271-275, 2020 05 16.
Article in En | MEDLINE | ID: mdl-31953835
ABSTRACT

PURPOSE:

Mismatch repair (MMR) is one of the DNA repair systems that correct mispaired bases during DNA replication errors. Polymorphisms in genes can increase susceptibility to the development of prostate cancer (PCa). In this study, we investigated mutL homolog 1 (MLH1) -93G>A (rs1800734) and mutS homolog 3 (MSH3) (rs26279) polymorphisms with the risk of PCa. MATERIALS AND

METHODS:

In this study of Iranian population, 175 histopathologically confirmed (PCa) patients and 230 benign prostate hyperplasia (BPH) as the controls were recruited. The genotypes of MLH1 and MSH3 were determined by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method.

RESULTS:

There was no significant difference of MLH1 (P = 0.4) and MSH3 (P?=?0.5) genotype distributions among PCa cases and controls. And also patients with PCa were not significant differences compared to those without in stage of cancer, grade of tumor, perineural invasion, and vascular invasion.

CONCLUSION:

Our results did not show adequate evidence for any significant association of MLH1 and MSH3 polymorphisms and PCa .
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Polymorphism, Restriction Fragment Length / Genetic Predisposition to Disease / DNA Mismatch Repair / MutL Protein Homolog 1 / MutS Homolog 3 Protein Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Urol J Journal subject: UROLOGIA Year: 2020 Document type: Article Affiliation country: Iran

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Polymorphism, Restriction Fragment Length / Genetic Predisposition to Disease / DNA Mismatch Repair / MutL Protein Homolog 1 / MutS Homolog 3 Protein Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Urol J Journal subject: UROLOGIA Year: 2020 Document type: Article Affiliation country: Iran